Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Rouen – page 50

646 clinical trials in Rouen, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Rouen at a glance
646
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

646 trials in Rouen

Open in trial search

Dermatitis atopic

Not recruiting

Study on the Effects of LEO 138559 for Adults with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Humanised Igg1 Monoclonal Antibody Against Interleukin 22 Receptor Subunit Alpha
  • Sponsor:Leo Pharma A/S

Diffuse large B-cell lymphoma refractory

Not recruiting

Study on Brentuximab Vedotin, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Brentuximab Vedotin
  • Sponsor:Seagen Inc.

Rheumatoid arthritis

Not recruiting

Study Comparing Upadacitinib and Adalimumab for Adults with Moderate to Severe Rheumatoid Arthritis Not Responding to a Single TNF Inhibitor

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Binge eating

Not recruiting

Study on BP1.4979 for Treating Binge Eating Disorder in Women with Moderate to Severe Symptoms

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:N-[4-[2-[4-(3-Cyanophenyl)Piperazin-1-Yl]Ethyl]Cyclohexyl]-3-Methoxypropanamide
  • Sponsor:Bioprojet Pharma

Bronchiectasis+1

Not recruiting

Study on the Safety and Tolerance of BI 1291583 in Adults with Cystic Fibrosis Bronchiectasis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:BI 1291583
  • Sponsor:Boehringer Ingelheim Espana S.A.

Diffuse large B-cell lymphoma+2

Not recruiting

Study of Glofitamab and Obinutuzumab for Patients with Relapsed or Refractory Lymphomas After CAR T-cell Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:LYSARC

Chronic lymphocytic leukaemia

Not recruiting

Study Comparing Obinutuzumab and Venetoclax with Obinutuzumab and Chlorambucil for Untreated Chronic Lymphocytic Leukemia Patients with Other Health Conditions

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Chlorambucil
  • Sponsor:F. Hoffmann-La Roche AG

Pleural mesothelioma

Not recruiting

Study of Volrustomig with Carboplatin and Pemetrexed for Patients with Unresectable Pleural Mesothelioma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Myelodysplastic syndrome

Not recruiting

Study on Venetoclax and Azacitidine for Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Adenocarcinoma gastric+1

Not recruiting

Study of Pembrolizumab, Trastuzumab, and Chemotherapy for Patients with HER2 Positive Advanced Stomach or Gastroesophageal Junction Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Multiple sclerosis+2

Not recruiting

Study on the Effectiveness and Safety of Ocrelizumab, Methylprednisolone, and Diphenhydramine Hydrochloride in Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Methylprednisolone
  • Sponsor:F. Hoffmann-La Roche AG

Transitional cell cancer of the renal pelvis and ureter

Not recruiting

Study of Sacituzumab Govitecan for Patients with Advanced or Metastatic Bladder Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Gilead Sciences Inc.

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Rouen

What the registry says about research in the country

01 Oncology Research

Clinical trials focusing on innovative treatments for various cancers, including head and neck squamous cell carcinoma, bladder cancer, and breast cancer. Studies are evaluating novel therapeutic combinations and targeted approaches.

  • Advanced cancer therapies
  • Immunotherapy combinations
  • Treatment resistance strategies

Multiple studies are investigating new drug combinations and personalized treatment approaches.

02 Neurology Studies

Research initiatives examining treatments for Alzheimer's disease, frontotemporal dementia, and multiple sclerosis. Studies focus on understanding disease mechanisms and testing novel therapeutic approaches.

  • Brain imaging techniques
  • Disease modification strategies
  • Synaptic density analysis

Innovative approaches using advanced imaging and biomarker analysis are being explored.

03 Cardiovascular Research

Studies investigating treatments for heart failure prevention and pulmonary hypertension. Research includes evaluation of new therapeutic agents and combination treatments.

  • Preventive interventions
  • Long-term safety studies
  • Antiplatelet therapy optimization

Focus on developing safer and more effective cardiovascular treatments.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.